OMICS and brain tumour biomarkers
暂无分享,去创建一个
Franklyn A Howe | Alison Loosemore | F. Howe | M. Papadopoulos | B. Bell | V. Petřík | A. Loosemore | B Anthony Bell | Marios C Papadopoulos | B. Bell | Vladimir Petrik
[1] D. Botstein,et al. A gene expression database for the molecular pharmacology of cancer , 2000, Nature Genetics.
[2] L Verhey,et al. Serial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery. , 2001, AJNR. American journal of neuroradiology.
[3] P. Davidsson,et al. Elevated Levels of alpha-2-Heremans-Schmid Glycoprotein in CSF of Patients with Low-Grade Gliomas , 2003, Tumor Biology.
[4] F. Kokocinski,et al. Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. , 2004, Cancer research.
[5] Wei Huang,et al. Functional outcomes and survival in patients with high-grade gliomas in dominant and nondominant hemispheres. , 2005, Journal of neurosurgery.
[6] M. Bernstein,et al. Failed stereotactic biopsy in a series of 518 cases. , 1995, Stereotactic and functional neurosurgery.
[7] E. Petricoin,et al. Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.
[8] E. Petricoin,et al. Clinical potential of proteomics in the diagnosis of ovarian cancer , 2002, Expert review of molecular diagnostics.
[9] A. Alaiya,et al. Clinical cancer proteomics: promises and pitfalls. , 2005, Journal of proteome research.
[10] I. Whittle,et al. Pineal region tumors and the role of stereotactic biopsy: review of the mortality, morbidity, and diagnostic rates in 370 cases. , 1998, Neurosurgery.
[11] P. Graham. Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults , 1993, Cancer.
[12] Timothy Planche,et al. A novel and accurate diagnostic test for human African trypanosomiasis , 2004, The Lancet.
[13] P. Angenendt. Progress in protein and antibody microarray technology. , 2005, Drug discovery today.
[14] M. Bernstein,et al. Complications of CT-guided stereotactic biopsy of intra-axial brain lesions. , 1994, Journal of neurosurgery.
[15] Liliana Gheorghiu,et al. Reduction of the concentration difference of proteins in biological liquids using a library of combinatorial ligands , 2005, Electrophoresis.
[16] Enrique Querol,et al. Identification of protein ligands in complex biological samples using intensity-fading MALDI-TOF mass spectrometry. , 2003, Analytical chemistry.
[17] W. Hall,et al. Preliminary assessment of turbo spectroscopic imaging for targeting in brain biopsy. , 2001, AJNR. American journal of neuroradiology.
[18] Allan J. Hamilton,et al. Stereotactic Biopsy of Intracranial Brain Lesions , 1999, Stereotactic and Functional Neurosurgery.
[19] F. Valafar. Pattern Recognition Techniques in Microarray Data Analysis : A Survey , 2002 .
[20] N. Seki,et al. Cathepsin D is a potential serum marker for poor prognosis in glioma patients. , 2005, Cancer research.
[21] S. Nelson,et al. DNA-microarray analysis of brain cancer: molecular classification for therapy , 2004, Nature Reviews Neuroscience.
[22] A. Butte,et al. Discovering functional relationships between RNA expression and chemotherapeutic susceptibility using relevance networks. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[23] Yu Shyr,et al. Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. , 2005, Cancer research.
[24] O. Kallioniemi,et al. Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. , 2000, Cancer research.
[25] A. von Deimling,et al. Molecular Genetic Analysis of Oligodendroglial Tumors , 2005, Journal of neuropathology and experimental neurology.
[26] Mark R Gilbert,et al. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. , 2002, Cancer research.
[27] S. Green,et al. Glioblastoma multiforme and anaplastic astrocytoma pathologic criteria and prognostic implications , 1985, Cancer.
[28] Debashis Ghosh,et al. Autoantibody signatures in prostate cancer. , 2005, The New England journal of medicine.
[29] L. Liotta,et al. CSF proteome: a protein repository for potential biomarker identification , 2005, Expert review of proteomics.
[30] E. Alexander,et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. , 1978, Journal of neurosurgery.
[31] A. Larsson,et al. Growth factor analysis of low-grade glioma CSF: PDGF and VEGF are not detectable , 2003, Neurological Sciences.
[32] Webster K. Cavenee,et al. Pathology and genetics of tumours of the nervous system. , 2000 .
[33] Xiao-Ying Meng,et al. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays , 2005, International journal of cancer.
[34] Anthony Asher,et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. , 2003, Journal of neurosurgery.
[35] M. Papadopoulos,et al. Emerging molecular mechanisms of brain tumour oedema. , 2001, British journal of neurosurgery.
[36] M. Brada. Pathology and Genetics of Tumours of the Nervous System , 2001, British Journal of Cancer.
[37] L. Arckens,et al. Proteomic approaches in brain research and neuropharmacology. , 2004, European journal of pharmacology.
[38] Nathalie Wong,et al. Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study. , 2005, Clinical chemistry.
[39] D. Koller,et al. From signatures to models: understanding cancer using microarrays , 2005, Nature Genetics.
[40] W. Hop,et al. Low-Molecular Weight Caldesmon as a Potential Serum Marker for Glioma , 2005, Clinical Cancer Research.
[41] T. Barrette,et al. Mining for regulatory programs in the cancer transcriptome , 2005, Nature Genetics.
[42] Susan M. Chang,et al. Serial proton magnetic resonance spectroscopy imaging of glioblastoma multiforme after brachytherapy. , 1997, Journal of neurosurgery.
[43] L. Liau,et al. Cellular immunity and immunotherapy of brain tumors. , 2004, Frontiers in bioscience : a journal and virtual library.
[44] Rob Pieters,et al. Identification of Tumor‐Related Proteins by Proteomic Analysis of Cerebrospinal Fluid from Patients with Primary Brain Tumors , 2003, Journal of neuropathology and experimental neurology.
[45] P. Thibault,et al. Identification of differentially expressed proteins in human glioblastoma cell lines and tumors , 2003, Glia.
[46] F. Heppner,et al. Gene expression profiling and subgroup identification of oligodendrogliomas , 2004, Oncogene.
[47] Stefan Müllner,et al. Protein biochips: A new and versatile platform technology for molecular medicine. , 2005, Drug discovery today.
[48] L. Stewart,et al. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials , 2002, The Lancet.
[49] M. Oshimura,et al. Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. , 2003, Biochemical and biophysical research communications.
[50] T. Poggio,et al. Prediction of central nervous system embryonal tumour outcome based on gene expression , 2002, Nature.
[51] A. Chinnaiyan,et al. Integrative analysis of the cancer transcriptome , 2005, Nature Genetics.
[52] Witham,et al. Comprehensive assessment of hemorrhage risks and outcomes after stereotactic brain biopsy. , 2001, Journal of neurosurgery.
[53] F Ståhlberg,et al. Proton MR spectroscopy and preoperative diagnostic accuracy: an evaluation of intracranial mass lesions characterized by stereotactic biopsy findings. , 2000, AJNR. American journal of neuroradiology.
[54] P J Kelly,et al. Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. , 1993, Journal of neurosurgery.
[55] L. Liau,et al. Tumor immunology, immunomics and targeted immunotherapy for central nervous system malignancies , 2005, Neurological research.
[56] Daniel B Vigneron,et al. In vivo molecular imaging for planning radiation therapy of gliomas: An application of 1H MRSI , 2002, Journal of magnetic resonance imaging : JMRI.
[57] F. Valafar. Pattern Recognition Techniques in Microarray Data Analysis , 2002 .
[58] W P Dillon,et al. Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens. , 2001, AJNR. American journal of neuroradiology.
[59] J. Mesirov,et al. Chemosensitivity prediction by transcriptional profiling , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[60] P. Black,et al. Neuroimaging in pediatric brain tumors: Gd-DTPA-enhanced, hemodynamic, and diffusion MR imaging compared with MR spectroscopic imaging. , 2002, AJNR. American journal of neuroradiology.
[61] P. Warnke,et al. Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme. , 1993, Journal of neurosurgery.
[62] M. Izquierdo,et al. Parent Phenotype and Age Dependence, on Rat Glioma Tumor Rejection , 2004, Journal of Neuro-Oncology.
[63] D. Botstein,et al. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[64] Glyn Johnson,et al. High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging. , 2002, Radiology.
[65] Z L Gokaslan,et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. , 2001, Journal of neurosurgery.
[66] V. L. Doyle,et al. Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy , 2003, Magnetic resonance in medicine.
[67] K. Laxer. Clinical Applications of Magnetic Resonance Spectroscopy , 1997, Epilepsia.
[68] P. Wesseling,et al. Neuropathological diagnostic accuracy , 2002, British journal of neurosurgery.
[69] M. Zweig,et al. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. , 1993, Clinical chemistry.
[70] Akira Yamaura,et al. Molecular Classification and Survival Prediction in Human Gliomas Based on Proteome Analysis , 2004, Cancer Research.
[71] Shu Zheng,et al. Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population or brain benign tumor. , 2005, Journal of Zhejiang University. Science. B.
[72] L. D.,et al. Brain tumors , 2005, Psychiatric Quarterly.
[73] P. Lichter,et al. Gene expression patterns in ependymomas correlate with tumor location, grade, and patient age. , 2003, The American journal of pathology.
[74] C. Gladson,et al. Endogenous inhibitors of angiogenesis in malignant gliomas: nature's antiangiogenic therapy. , 2005, Neuro-oncology.
[75] M. Pfreundschuh,et al. Human neoplasms elicit multiple specific immune responses in the autologous host. , 1995, Proceedings of the National Academy of Sciences of the United States of America.